{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T15:52:20Z","timestamp":1758815540670},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2020,2,29]],"date-time":"2020-02-29T00:00:00Z","timestamp":1582934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"},{"start":{"date-parts":[[2020,2,29]],"date-time":"2020-02-29T00:00:00Z","timestamp":1582934400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jsm.jsexmed.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>A subset of patients with Peyronie's disease (PD) treated with collagenase clostridium histolyticum (CCH) experience persistent bother and some require surgery.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>We characterize patients experiencing persistent bother after CCH treatment and identify associations and predictors of surgical intervention\/outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We retrospectively identified patients with PD from October 2014 to October 2019 and identified those presenting with persistent bother after CCH treatment by other urologists. Intracavernosal injection and penile Doppler ultrasonography were performed, and subsequent interventions\/outcomes were recorded. Baseline characteristics were compared with Student t-test and chi-square test. Predictors of surgical intervention and complications were assessed using multivariable logistic regression.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Outcomes<\/jats:title>\n                  <jats:p>The primary outcome was surgery after CCH treatment. Secondary outcomes included worsened erectile function, sensory deficits, and penile length change.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 573, 67 (11.7%) patients with PD had undergone prior CCH treatment with median 6 injections (range 2\u201324). Mean post-CCH PD Questionnaire bother score was 10.1 (SD: 3.1), and total International Index of Erectile Function-5 was 15.3 (SD: 8.7). Mean PD duration was 27.8 (SD: 35.7) months, with a mean composite curvature (MCC) of 69.0\u00b0 (SD: 33.8) measured after injection. Of 67, 44\u00a0(65.7%) patients had MCC &amp;gt;60\u00b0. Of 67, 52 (77.6%) patients had indent, narrowing, or hourglass and 26\u00a0(38.8%) had hinge effect (buckling of the erect penis with axial pressure) on examination. Calcification was identified in 26 of 67 (38.8%) patients, with grade 3 calcifications comprising 6 of 23 (26.1%) patients. Of 67, 33 (49.3%) patients underwent surgery, with 20 (60.1%) undergoing partial plaque excision and grafting with\/without tunica albuginea plication, 6 (18.2%) undergoing tunica albuginea plication alone, and 7\u00a0(21.2%) undergoing penile prosthesis with plaque incision and grafting. Surgical patients had greater mean curvature (82.6 vs 55.4, P\u00a0=\u00a0.001) and were more likely to have hinge (54.5% vs 20.6%, P\u00a0=\u00a0.005). On multivariable analysis, MCC \u226560\u00b0 predicted patient\u2019s decision for surgery (odds ratio: 2.99, P\u00a0&amp;lt;\u00a0.01, 95% confidence interval: 1.62\u20134.35). There were no associations between surgical complications and number of injections or CCH-associated adverse events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Implications<\/jats:title>\n                  <jats:p>Patients presenting with persistent bother after CCH treatment often have narrowing and calcifications (despite calcifications being a contraindication to CCH treatment), and those who have hinge or severe curvature are more likely to undergo surgery with low rates of complications.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Strengths\/Limitations<\/jats:title>\n                  <jats:p>This study's generalizability is limited by selection bias, but useful data are provided for patient counseling.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Patients with persistent bother after CCH treatment had high rates of indentation\/narrowing, plaque calcifications, and MCC &amp;gt;60\u00b0 at completion of CCH treatment. Surgical intervention is more common with hinge and is safe and feasible in these patients, with low rates of complications. These findings suggest possible negative prognostic factors for CCH treatment, which merit further investigation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1016\/j.jsxm.2020.02.002","type":"journal-article","created":{"date-parts":[[2020,2,29]],"date-time":"2020-02-29T21:38:00Z","timestamp":1583012280000},"page":"1005-1011","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Characteristics of Men with Peyronie's Disease and Collagenase Clostridium Histolyticum Treatment Failure: Predictors of Surgical Intervention and Outcomes"],"prefix":"10.1093","volume":"17","author":[{"given":"Petar","family":"Bajic","sequence":"first","affiliation":[{"name":"Division of Urology , Chicago, IL , USA"},{"name":"Rush University Medical Center , Chicago, IL , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam B.","family":"Wiggins","sequence":"additional","affiliation":[{"name":"Division of Urology , Chicago, IL , USA"},{"name":"Rush University Medical Center , Chicago, IL , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew J.","family":"Ziegelmann","sequence":"additional","affiliation":[{"name":"Department of Urology , Rochester, MN , USA"},{"name":"Mayo Clinic , Rochester, MN , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence A.","family":"Levine","sequence":"additional","affiliation":[{"name":"Division of Urology , Chicago, IL , USA"},{"name":"Rush University Medical Center , Chicago, IL , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,2,29]]},"reference":[{"key":"2023011111091198700_bib1","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ucl.2007.08.017","article-title":"Peyronie\u2019s disease","volume":"34","author":"Taylor","year":"2007","journal-title":"Urol Clin North Am"},{"key":"2023011111091198700_bib2","doi-asserted-by":"publisher","DOI":"10.1016\/j.sxmr.2019.06.004","article-title":"The etiology of Peyronie\u2019s disease: pathogenesis and genetic contributions","author":"Sharma","year":"2019","journal-title":"Sex Med Rev"},{"key":"2023011111091198700_bib3","doi-asserted-by":"crossref","first-page":"282503","DOI":"10.1155\/2011\/282503","article-title":"A\u00a0population-based study of Peyronie\u2019s disease: prevalence and treatment patterns in the United States","volume":"2011","author":"Dibenedetti","year":"2011","journal-title":"Adv Urol"},{"key":"2023011111091198700_bib4","doi-asserted-by":"crossref","first-page":"46","DOI":"10.21037\/tau.2016.11.01","article-title":"Understanding the cellular basis and pathophysiology of Peyronie\u2019s disease to optimize treatment for erectile dysfunction","volume":"6","author":"Campbell","year":"2017","journal-title":"Transl Androl Urol"},{"key":"2023011111091198700_bib5","first-page":"1977","article-title":"Impact of Peyronie\u2019s disease on sexual and psychosocial functioning: qualitative findings in patients and controls","volume":"5","author":"Rosen","year":"2008","journal-title":"J\u00a0Sex Med"},{"key":"2023011111091198700_bib6","first-page":"653","article-title":"Psychological impact of Peyronie\u2019s disease: a review","volume":"10","author":"Nelson","year":"2013","journal-title":"J\u00a0Sex Med"},{"key":"2023011111091198700_bib7","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41585-018-0117-7","article-title":"Nonsurgical management of Peyronie\u2019s disease","volume":"16","author":"Tsambarlis","year":"2019","journal-title":"Nat Rev Urol"},{"key":"2023011111091198700_bib8","doi-asserted-by":"crossref","DOI":"10.1177\/1756287218823671","article-title":"Non-invasive treatment in the management of Peyronie\u2019s disease","volume":"11","author":"Randhawa","year":"2019","journal-title":"Ther Adv Urol"},{"key":"2023011111091198700_bib9","first-page":"111","article-title":"Impact of the advent of collagenase clostridium histolyticum on the surgical management of Peyronie\u2019s disease: a population-based analysis","volume":"17","author":"Sukumar","year":"2020","journal-title":"J\u00a0Sex Med"},{"key":"2023011111091198700_bib10","first-page":"745","article-title":"Peyronie\u2019s disease: AUA guideline","volume":"194","author":"Nehra","year":"2015","journal-title":"J\u00a0Urol"},{"key":"2023011111091198700_bib11","first-page":"199","article-title":"Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies","volume":"190","author":"Gelbard","year":"2013","journal-title":"J\u00a0Urol"},{"key":"2023011111091198700_bib12","first-page":"56","article-title":"Collagenase versus placebo in the treatment of Peyronie\u2019s disease: a double-blind study","volume":"149","author":"Gelbard","year":"1993","journal-title":"J\u00a0Urol"},{"key":"2023011111091198700_bib13","first-page":"180","article-title":"The use of intralesional clostridial collagenase injection therapy for Peyronie\u2019s disease: a prospective, single-center, non-placebo-controlled study","volume":"5","author":"Jordan","year":"2008","journal-title":"J\u00a0Sex Med"},{"key":"2023011111091198700_bib14","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00345-019-02850-3","article-title":"Characteristics predictive of response to collagenase clostridium histolyticum for Peyronie\u2019s disease: a review of the literature","volume":"38","author":"Masterson","year":"2020","journal-title":"World J Urol"},{"key":"2023011111091198700_bib15","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/bju.13096","article-title":"Clinical efficacy of collagenase Clostridium histolyticum in the treatment of Peyronie\u2019s disease by subgroup: results from two large, double-blind, randomized, placebo-controlled, phase III studies","volume":"116","author":"Lipshultz","year":"2015","journal-title":"BJU Int"},{"key":"2023011111091198700_bib16","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.urology.2018.06.003","article-title":"Plaque calcification: an important predictor of collagenase clostridium histolyticum treatment outcomes for men with Peyronie\u2019s disease","volume":"119","author":"Wymer","year":"2018","journal-title":"Urology"},{"key":"2023011111091198700_bib17","first-page":"3121","article-title":"Peyronie\u2019s disease plaque calcification-prevalence, time to identification, and development of a new grading classification","volume":"10","author":"Levine","year":"2013","journal-title":"J\u00a0Sex Med"},{"key":"2023011111091198700_bib18","first-page":"2149","article-title":"A\u00a0surgical algorithm for the treatment of Peyronie\u2019s disease","volume":"158","author":"Levine","year":"1997","journal-title":"J\u00a0Urol"},{"key":"2023011111091198700_bib19","first-page":"e681","article-title":"1656 clinical evaluation of treatment of Peyronie's disease with collagenase clostridium histolyticum: analysis of penile curvature deformity by duration of disease and plaque calcification","volume":"189","author":"Goldstein","year":"2013","journal-title":"J\u00a0Urol"},{"key":"2023011111091198700_bib20","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/andr.12497","article-title":"Collagenase clostridium histolyticum for the treatment of Peyronie\u2019s disease: a prospective Italian multicentric study","volume":"6","author":"Capece","year":"2018","journal-title":"Andrology"},{"key":"2023011111091198700_bib21","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.urology.2017.08.037","article-title":"Successful treatment of residual curvature in peyronie disease in men previously treated with intralesional collagenase clostridium histolyticum","volume":"110","author":"DeLay","year":"2017","journal-title":"Urology"},{"key":"2023011111091198700_bib22","first-page":"259","article-title":"Surgical correction of persistent Peyronie\u2019s disease following collagenase clostridium histolyticum treatment","volume":"12","author":"Levine","year":"2015","journal-title":"J\u00a0Sex Med"},{"key":"2023011111091198700_bib23","first-page":"1021","article-title":"Surgical outcomes of plaque excision and grafting and supplemental tunica albuginea plication for treatment of Peyronie\u2019s disease with severe compound curvature","volume":"15","author":"Chow","year":"2018","journal-title":"J\u00a0Sex Med"},{"key":"2023011111091198700_bib24","first-page":"1491","article-title":"Penile sensory changes after plaque incision and grafting surgery for Peyronie\u2019s disease","volume":"15","author":"Terrier","year":"2018","journal-title":"J\u00a0Sex Med"},{"key":"2023011111091198700_bib25","first-page":"252","article-title":"750: managing penile shortening after Peyronie\u2019s disease surgery","volume":"177","author":"Moncada-Iribarren","year":"2007","journal-title":"J\u00a0Urol"},{"key":"2023011111091198700_bib26","first-page":"2396","article-title":"A\u00a0retrospective comparative study of traction therapy vs. no traction following tunica albuginea plication or partial excision and grafting for Peyronie\u2019s disease: measured lengths and patient perceptions","volume":"9","author":"Rybak","year":"2012","journal-title":"J\u00a0Sex Med"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609520300679?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609520300679?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/17\/5\/1005\/48527080\/jsm_17_5_1005.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/17\/5\/1005\/48527080\/jsm_17_5_1005.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T14:44:13Z","timestamp":1675953853000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/17\/5\/1005\/6973785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,29]]},"references-count":26,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,2,29]]},"published-print":{"date-parts":[[2020,5,1]]}},"URL":"https:\/\/doi.org\/10.1016\/j.jsxm.2020.02.002","relation":{},"ISSN":["1743-6109","1743-6095"],"issn-type":[{"value":"1743-6109","type":"electronic"},{"value":"1743-6095","type":"print"}],"subject":[],"published-other":{"date-parts":[[2020,5]]},"published":{"date-parts":[[2020,2,29]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characteristics of Men With Peyronie's Disease and Collagenase Clostridium Histolyticum Treatment Failure: Predictors of Surgical Intervention and Outcomes","name":"articletitle","label":"Article Title"},{"value":"The Journal of Sexual Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsxm.2020.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}